The effects and efficacy of Nerandomilast-Jascayd

Nerandomilast (Nerandomilast)-Jascayd is a new type of drug mainly used to treat idiopathic pulmonary fibrosis (IPF). Its main mechanism of action is through selective inhibition of phosphodiesterase 4 (PDE4), especially the preferential inhibition of PDE4B isoenzyme. Compared with other enzymes of the same type (such as PDE4A, PDE4C and PDE4D), Nerandomilast's inhibitory effect on PDE4B is at least 9 times stronger, making it particularly effective in regulating intracellular signaling.

The main function of PDE4 enzyme in the body is to hydrolyze and inactivate cyclic adenosine monophosphate (cAMP), which is an important cell signaling molecule involved in regulating various physiological processes. By inhibiting PDE4B, Nerandomilast can increase intracellular cAMP levels, thereby reducing the expression of profibrotic growth factors and inflammatory cytokines. These factors are often present in excess in patients with idiopathic pulmonary fibrosis, leading to the progression of fibrosis in the lung tissue. Therefore, the anti-fibrosis and immunomodulatory effects of Nerandomilast are of great significance for improving the condition of IPF patients.

In clinical studies,The efficacy of Nerandomilast has been significantly verified. In comparison with the placebo group, the decrease in absolute change from baseline in forced vital capacity (FVC) over 52 weeks was statistically significant in patients taking Namilast Tablets , indicating that patients taking Namilast Tablets had a significantly lower decrease in lung function than patients who did not receive treatment. This is an important treatment development for IPF patients, because IPF is a progressive disease, and the maintenance of lung function is directly related to the patient's quality of life and survival.

The application of namilast tablets is not limited to its effect on pulmonary fibrosis. It also has potential immunomodulatory functions, which may provide new ideas for the treatment of other inflammation-related diseases. In addition, with more in-depth research on the mechanism of action of Nerandomilast, the potential application of this drug in other fields may be discovered in the future.

Reference materials:https://www.drugs.com/jascayd.html